TP53 and B-cell chronic lymphocytic leukemia: Among CLL genetic lesions, TP53 abnormalities and IGHV mutational status currently fulfill the criteria of predictive biomarkers whose usage is recommended by guidelines for the clinical management of CLL [21,39].